论文部分内容阅读
目的 :评价头孢曲松和头孢哌酮治疗病毒伴细菌感染性肺炎的成本—效果比。方法 :采用回顾性分析 ,选择 30例病毒伴细菌感染性肺炎患者 ,分为头孢曲松组和头孢哌酮组 ,运用药物经济学的成本 效果分析方法进行评价。结果 :头孢曲松 (曲沙 )治疗病毒伴细菌感染性肺炎优于头孢哌酮 (先锋必 ) ,是一种成本 效果较好的药物。结论 :药物经济学在临床药物治疗过程中 ,拟定出合理的成本 效果处方 ,为临床合理用药提供了客观依据
OBJECTIVE: To evaluate the cost-effectiveness of ceftriaxone and cefoperazone in the treatment of bacterial infections with pneumonia. Methods: A retrospective analysis of 30 patients with bacterial pneumonia was selected and divided into ceftriaxone group and cefoperazone group. The cost-effectiveness analysis method was used to evaluate the efficacy of the drug. Results: Ceftriaxone (TRS) was superior to cefoperazone (Pioneer) in the treatment of virus-associated bacterial pneumonia and was a cost-effective drug. Conclusion: Pharmacoeconomics in the course of clinical drug treatment, to formulate a reasonable cost-effective prescription, to provide an objective basis for clinical rational use of drugs